Trial Profile
A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With alpha-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary) ; Voglibose
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda
- 17 Dec 2010 New source identified and integrated (ClinicalTrials.gov, NCT01263483).
- 17 Dec 2010 Actual initiation date (Jan 2007) added as reported by ClinicalTrials.gov.
- 13 Oct 2010 New trial record